+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Inhibition of isoproterenol activation of adenylate cyclase by metoprolol, oxprenolol, and the para isomer of oxprenolol



Inhibition of isoproterenol activation of adenylate cyclase by metoprolol, oxprenolol, and the para isomer of oxprenolol



Molecular Pharmacology 12(2): 203-207




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 038950451

Download citation: RISBibTeXText

PMID: 4723


Related references

Comparison of the beta-adrenoceptor blocking activity of oxprenolol, slow release oxprenolol and a combined oxprenolol diuretic preparation. British Journal of Clinical Pharmacology 12(6): 869-871, 1981

Cardiospecificity of -receptor blockade. A comparison of the relative potencies on cardiac and peripheral vascular -adrenoceptors of propranolol, of practolol and its ortho-substituted isomer, and of oxprenolol and its para-substituted isomer. Cardiovascular Research 7(2): 226-240, 1973

Cardio specificity of beta receptor blockade a comparison of the relative potencies on cardiac and peripheral vascular beta adrenoceptors of propranolol of practolol and its ortho substituted isomer and of oxprenolol and its para substituted isomer. Cardiovascular Research: 226-240, 1973

Comparative study of atenolol, metoprolol, metoprolol durules, and slow-release oxprenolol in essential hypertension. British Heart Journal 46(5): 498-502, 1981

Comparison of a slow-release formulation of oxprenolol with conventional oxprenolol in the treatment of hypertension. Clinical Science and Molecular Medicine. Supplement 3: 559s-561s, 1976

A comparison of slow release oxprenolol with conventional oxprenolol in the treatment of hypertension. European Journal of Clinical Pharmacology 14(2): 77-82, 1978

Suppression of conditioned hyper thermic response by l oxprenolol and d oxprenolol in rats. Experientia (Basel) 30(6): 695, 1974

Slow-release oxprenolol compared with oxprenolol in hypertensive patients: a multicenter clinical trial. Drug Intelligence and Clinical Pharmacy 17(1): 51-54, 1983

Simultaneous determination of oxprenolol and 2H6-labelled oxprenolol in human plasma by gas chromatography/mass spectrometry. Biomedical Mass Spectrometry 12(6): 269-273, 1985

A comparison of slow Trasicor (oxprenolol 160 mg) and Trasidrex (oxprenolol 160 mg and cyclopenthiazide 0.25 mg) in the treatment of hypertension in general practice. Journal of International Medical Research 9(5): 315-318, 1981

Comparison of the activity and plasma levels of oxprenolol slow release oxprenolol long acting propranolol and sotalol. European Journal of Clinical Pharmacology 17(6): 419-424, 1980

Reproducibility of oxprenolol plasma concentrations in young female volunteers following oral administration of an oxprenolol Oros dosage form. British Journal of Clinical Pharmacology 19 Suppl 2: 185s-190s, 1985

Relationship between the rate of appearance of oxprenolol in the systemic circulation and the location of an oxprenolol Oros 16/260 drug delivery system within the gastrointestinal tract as determined by scintigraphy. British Journal of Clinical Pharmacology 26(4): 435-443, 1988

The dopamine sensitive adenylate cyclase of the rat caudate nucleus part 2 a comparison with the isoproterenol sensitive beta adenylate cyclase of the rat erythrocyte for inhibition or stimulation by tetra hydro iso quinolines. Molecular Pharmacology 12(5): 854-861, 1976

Slow release oxprenolol in angina pectoris: study comparing oxprenolol, once daily, with propranolol, four times daily. American Journal of Cardiology 47(5): 1123-1127, 1981